Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab plus chlorambucil versus chlorambucil alone in previously untreated chronic lymphocytic leukemia
2008-004932-19Phase 3Terminated
- Sponsor
- GSK
- Start
- Oct 2008
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) comparing Ofatumumab + chlorambucil with Chlorambucil monotherapy (2 arms). Primary endpoint: Progression-free survival. Started Oct 2008; status: terminated.
02
Drugs
ofatumumabchlorambucil
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2008-004932-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-004932-19.